Type A Meeting Request submitted to FDA to Review Proposed Study Design for a Second Ph 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
“During the Type A meeting in April, FDA expressed its understanding of the need for additional therapies in CTCL and its willingness to work with Soligenix. FDA provided significant insights into its thoughts on a clinical study design allowing our team to prepare a comprehensive proposal expeditiously,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We certainly appreciate the FDA’s responsiveness and continued collaboration demonstrated by categorizing this meeting as a Type A meeting. The proposed protocol for the confirmatory study retains the key design aspects from the FLASH study while addressing as much of the FDA’s initial feedback as feasible. We look forward to having a productive meeting with the FDA and obtaining agreement on a pivotal study design that is highly executable as quickly as possible.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
